For example, reactivation of the MAPK pathway downstream of BRAF via MEK or ERK mutations has been documented in patients progressing on BRAF/MEK inhibitors, underscoring the adaptive plasticity of melanoma cells [235]. The gene discussed is BRAF; the disease is melanoma.